Contributions
Abstract: PB1673
Type: Publication Only
Background
The biological properties, genetic abnormalities of leukemic cells influence on their sensitivity to chemotherapeutic drugs. It is widely known that there can be significant differences both in genetic features as well as in drug resistance profile of individual tumors with the same phenotype.
Aims
The purpose of this study was to analyze the relationship between in vitro chemosensitivity test results using the Cell Titer-Glo assay and clinical response on chemotherapy, and to find the possibility of optimizing the treatment for individual patients according to their actual drug resistance.
Methods
For The Cell Titer-Glo assay, we obtained bone marrow aspirates or peripheral blood samples from 68 patients with newly diagnosed acute myeloid leukemia at the time of initial diagnosis. The following drugs were tested: cytarabine arabinoside, daunorubicin, idarubicin, fludarabine, etoposide, and methotrexate. We evaluated clinical response and survival outcome according to chemosensitivity of drugs and protein expression.
Results
In this study, in vitro chemosensitivity test with the Cell Titer-Glo assay showed the relationship between chemosensitivity and survival outcome significantly. The 5-year overall survival rates with dichotomized chemosensitivity of idarubicin (64.6% vs. 33.3%, p=0.046), cytarabine (63.1% vs. 43.3%, p=0.0291), and fludarabine (80.1% vs. 37.5%, p= 0.020) were higher in low centration level than in high concentration level. There was a tendency of higher relapse-free survival rate at 4-year in the patients with low level IC50 than in the high level IC50. However, cytotoxic effect of testing drugs in vitro by the Cell Titer-Glo assay did not show a relationship with complete remission rate after induction and leukemia recurrence rate.
Conclusion
Although the Cell Titer-Glo assay did not provide the prediction of clinical response of induction treatment, it can be a useful tool in individually optimizing the chemotherapy of patients with newly diagnosed acute myeloid leukemia.
Session topic: 4. Acute myeloid leukemia - Clinical
Keyword(s): Drug resistance, Chemosensitivity, Acute Myeloid Leukemia
Abstract: PB1673
Type: Publication Only
Background
The biological properties, genetic abnormalities of leukemic cells influence on their sensitivity to chemotherapeutic drugs. It is widely known that there can be significant differences both in genetic features as well as in drug resistance profile of individual tumors with the same phenotype.
Aims
The purpose of this study was to analyze the relationship between in vitro chemosensitivity test results using the Cell Titer-Glo assay and clinical response on chemotherapy, and to find the possibility of optimizing the treatment for individual patients according to their actual drug resistance.
Methods
For The Cell Titer-Glo assay, we obtained bone marrow aspirates or peripheral blood samples from 68 patients with newly diagnosed acute myeloid leukemia at the time of initial diagnosis. The following drugs were tested: cytarabine arabinoside, daunorubicin, idarubicin, fludarabine, etoposide, and methotrexate. We evaluated clinical response and survival outcome according to chemosensitivity of drugs and protein expression.
Results
In this study, in vitro chemosensitivity test with the Cell Titer-Glo assay showed the relationship between chemosensitivity and survival outcome significantly. The 5-year overall survival rates with dichotomized chemosensitivity of idarubicin (64.6% vs. 33.3%, p=0.046), cytarabine (63.1% vs. 43.3%, p=0.0291), and fludarabine (80.1% vs. 37.5%, p= 0.020) were higher in low centration level than in high concentration level. There was a tendency of higher relapse-free survival rate at 4-year in the patients with low level IC50 than in the high level IC50. However, cytotoxic effect of testing drugs in vitro by the Cell Titer-Glo assay did not show a relationship with complete remission rate after induction and leukemia recurrence rate.
Conclusion
Although the Cell Titer-Glo assay did not provide the prediction of clinical response of induction treatment, it can be a useful tool in individually optimizing the chemotherapy of patients with newly diagnosed acute myeloid leukemia.
Session topic: 4. Acute myeloid leukemia - Clinical
Keyword(s): Drug resistance, Chemosensitivity, Acute Myeloid Leukemia